PHF20

Across TCGA pan-cancer cohorts, PHF20 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHF20 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PHF20 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PHF20 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where PHF20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.581	.001	15	view →
PDAC	DFS	Tertile	II,III,IV	0.339	0.849	.024	6	view →
GBM	DFS	Median	All	0.140	0.346	.031	2	view →
LSCC	OS	Median	All	0.881	0.741	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PHF20–CCRCC (DFS)

Open the CCRCC breakdown →